Skip to main content
Article thumbnail
Location of Repository

Evaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care population

By Dr Sue Wilson, Michael J.O. Wakelam, Richard F. D. Hobbs, Angela V. Ryan, Janet A. Dunn, Val. D. Redman, Fiona Patrick, Lynne Colbourne and Ashley Martin

Abstract

Background\ud Bowel cancer is common and is a major cause of death. Meta-analysis of randomised controlled trials estimates that screening for colorectal cancer using faecal occult blood (FOB) test reduces mortality from colorectal cancer by 16%. However, FOB testing has a low positive predictive value, with associated unnecessary cost, risk and anxiety from subsequent investigation, and is unacceptable to a proportion of the target population. Increased levels of an enzyme called matrix metalloproteinase 9 (MMP-9) have been found to be associated with colorectal cancer, and this can be measured from a blood sample. Serum MMP-9 is potentially an accurate, low risk and cost-effective population screening tool. This study aims to evaluate the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care population.\ud \ud Methods/Design\ud People aged 50 to 69 years, who registered in participating general practices in the West Midlands Region, will be asked to complete a questionnaire that asks about symptoms. Respondents who describe any colorectal symptoms (except only abdominal bloating and/or anal symptoms) and are prepared to provide a blood sample for MMP9 estimation and undergo a colonoscopy (current gold standard investigation) will be recruited at GP based clinics by a research nurse. Those unfit for colonoscopy will be excluded. Colonoscopies will be undertaken in dedicated research clinics. The accuracy of MMP-9 will be assessed by comparing the MMP-9 level with the colonoscopy findings, and the combination of factors (e.g. symptoms and MMP-9 level) that best predict a diagnosis of malignancy (invasive disease or polyps) will be determined.\ud \ud Discussion\ud Colorectal cancer is a major cause of morbidity and mortality. Most colorectal cancers arise from adenomas and there is a period for early detection by screening, but available tests have risks, are unacceptable to many, have high false positive rates or are expensive.\ud \ud This study will establish the potential of serum MMP-9 as a screening test for colorectal cancer. If it is confirmed as accurate and acceptable, this serum marker has the potential to assist with reducing the morbidity and mortality from colorectal cancer.\u

Topics: RC0254
Publisher: BioMed Central Ltd.
Year: 2006
OAI identifier: oai:wrap.warwick.ac.uk:559

Suggested articles

Citations

  1. (2000). (Editor): General and Systematic Pathology Third edition. Churchill Livingstone;
  2. (2004). Committee: Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. [http://www.nsc.nhs.uk/uk_nsc/uk_nsc_ind.htm].
  3. (1996). Complications of colonoscopy and flexible sigmoidoscopy. Gastrointestinal endoscopy clinics of North America
  4. (1978). Feinstein AR: Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. doi
  5. (2000). for Veterans Affairs Cooperative Study Group: Use of colonoscopy to screen asymptomatic adults for colorectal cancer. The New England Journal of Medicine
  6. Health: Referral guidelines for suspected cancer. doi
  7. (2000). Health: The NHS Cancer Plan. doi
  8. (2006). Impending or pending? The national bowel cancer screening programme. BMJ doi
  9. Institute: Colon and rectum cancer (invasive). Survival rates, by race, sex, diagnosis, year, stage and age. [http://seer.cancer.gov/cgi-bin/csr/search.pl].
  10. (2001). Intelligence Centre: Deaths,
  11. (1998). JMA: Population based randomised study of uptake and yield of screening by flexible sigmoidoscopy compared with screening with faecal occult blood testing. BMJ doi
  12. (1996). Mangham CM: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet doi
  13. (2004). Morabia A: Spectrum bias: a quantitative and graphical analysis of the variability of medical diagnostic test performance. Statistics in Medicine doi
  14. (2003). Neugut AI: Risk of Perforation After Colonoscopy and Sigmoidoscopy: A Population-Based Study. doi
  15. (1999). NJ: Proteolysis in human breast and colorectal cancer. doi
  16. Office for National Statistics: Mid-2002 Population Estimates; quinary age groups and sex for local authorities in England and Wales; estimated resident population. [http://www.statis tics.gov.uk/statbase/Prod uct.asp?vlnk=10687&image.x=18&image.y=9].
  17. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/6/258/pre pub
  18. (2005). Referral guidelines for suspected cancer – quick reference guide.
  19. (1998). RJC: Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. doi
  20. (2003). Screening for colorectal cancer using the faecal occult blood test, Hemocult (Cochrane Reviews). doi
  21. (2002). Sigmoidoscopy Screening Trial Investigators: Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet doi
  22. (2001). Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. doi
  23. (1990). Szporn A: The National Polyp Study Workgroup. The National Polyp Study. Patient and Polyp Characteristics Associated With High-Grade Dysplasia in Colorectal Adenomas. Gastroenterology
  24. (2003). TH-H: A casecohort study for the disease natural history of adenoma-carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy. doi
  25. (2003). The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. doi
  26. (2004). UK colorectal cancer screening pilot group: Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. BMJ doi
  27. (2001). Urist MM: Role of Matrix Metalloproteinases in Colorectal Carcinogenesis. Annals of Surgery doi
  28. (1999). Vatn MH: Flexible sigmoidoscopy or colonoscopy as a screening modality for colorectal adenomas in older age groups? Findings in a cohort of the normal population aged 63–72 years. Gut doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.